{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:44:08Z","timestamp":1792539848700,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41375-018-0040-1","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T12:17:06Z","timestamp":1525263426000},"page":"1542-1560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network"],"prefix":"10.1038","volume":"32","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas F","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Waage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-8657","authenticated-orcid":false,"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf H.","family":"Mellqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Caers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"40_CR1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Multiple Myeloma. Version 1.2018. 2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma_blocks.pdf . Accessed 03 Oct 2017."},{"key":"40_CR2","unstructured":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Clinical safety data management: definitions and standards for expedited reporting. E2A. 1994. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2A\/Step4\/E2A_Guideline.pdf . Accessed 5 Dec 2016."},{"key":"40_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587\u2013600.","journal-title":"J Clin Oncol"},{"key":"40_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/leu.2013.293","volume":"28","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28:981\u201392.","journal-title":"Leukemia"},{"key":"40_CR5","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","volume":"117","author":"M Cavo","year":"2011","unstructured":"Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063\u201373.","journal-title":"Blood"},{"key":"40_CR6","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254\u201366.","journal-title":"Haematologica"},{"key":"40_CR7","unstructured":"National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. Version 1.2018. December 1. 2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf . Accessed 11. February 2018."},{"key":"40_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","volume":"154","author":"JA Snowden","year":"2011","unstructured":"Snowden JA, Ahmedzai SH, Ashcroft J, D\u2019Sa S, Littlewood T, Low E, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol. 2011;154:76\u2013103.","journal-title":"Br J Haematol"},{"key":"40_CR9","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Lacy MQ, Greipp PR. Multiple myeloma. In: Gertz MA, Greipp PR, editors. Hematologic malignancies: multiple myeloma and related plasma cell disorders. Berlin Heidelberg: Springer-Verlag; 2004. p. 55\u2013109.","DOI":"10.1007\/978-3-662-08885-2_3"},{"key":"40_CR10","unstructured":"European Medicines Agency. Thalidomide celgene: EPAR - product information. 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000823\/WC500037050.pdf . Accessed 10 Nov 2016."},{"key":"40_CR11","unstructured":"European Medicines Agency. Revlimid: EPAR - product information. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000717\/WC500056018.pdf . Accessed 03 Oct 2017."},{"key":"40_CR12","unstructured":"European Medicines Agency. Imnovid: EPAR - product information. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000717\/WC500056018.pdf . Accessed 03 Oct 2017."},{"key":"40_CR13","unstructured":"United States Food and Drug Administration. Thalidomide celgene: label information. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020785s051lbl.pdf . Accessed 10 Nov 2016."},{"key":"40_CR14","unstructured":"United States Food and Drug Administration. Revlimid: label information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021880s051lbl.pdf . Accessed 03 Oct 2017."},{"key":"40_CR15","unstructured":"United States Food and Drug Administration. Pomalyst: label information. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204026s012s014lbl.pdf . Accessed 03 Oct 2017."},{"key":"40_CR16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.2010.28.0792","volume":"29","author":"DC Johnson","year":"2011","unstructured":"Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011;29:797\u2013804.","journal-title":"J Clin Oncol"},{"key":"40_CR17","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","volume":"132","author":"A Glasmacher","year":"2006","unstructured":"Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006;132:584\u201393.","journal-title":"Br J Haematol"},{"key":"40_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/leu.2010.313","volume":"25","author":"P Kapoor","year":"2011","unstructured":"Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011;25:689\u201396.","journal-title":"Leukemia"},{"key":"40_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2012.067058","volume":"98","author":"A Palumbo","year":"2013","unstructured":"Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013;98:87\u201394.","journal-title":"Haematologica"},{"key":"40_CR20","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/S0305-7372(10)70009-8","volume":"36","author":"MV Mateos","year":"2010","unstructured":"Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev. 2010;36:S24\u201332.","journal-title":"Cancer Treat Rev"},{"key":"40_CR21","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906\u201317.","journal-title":"N Engl J Med"},{"key":"40_CR22","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1182\/blood-2014-06-583302","volume":"124","author":"C Pawlyn","year":"2014","unstructured":"Pawlyn C, Khan MS, Muls A, Sriskandarajah P, Kaiser MF, Davies FE, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood. 2014;124:2467\u20138.","journal-title":"Blood"},{"key":"40_CR23","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759\u201369.","journal-title":"N Engl J Med"},{"key":"40_CR24","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782\u201391.","journal-title":"N Engl J Med"},{"key":"40_CR25","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770\u201381.","journal-title":"N Engl J Med"},{"key":"40_CR26","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2012-04-421883","volume":"120","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood. 2012;120:1597\u20131600.","journal-title":"Blood"},{"key":"40_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","volume":"15","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15:333\u201342.","journal-title":"Lancet Oncol"},{"key":"40_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.114","volume":"6","author":"JR Jones","year":"2016","unstructured":"Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6:e506.","journal-title":"Blood Cancer J"},{"key":"40_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40262-016-0432-1","volume":"56","author":"N Chen","year":"2017","unstructured":"Chen N, Zhou S, Palmisano M. Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet. 2017;56:139\u201352.","journal-title":"Clin Pharmacokinet"},{"key":"40_CR30","unstructured":"European Medicines Agency. Velcade: EPAR - product information. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000539\/WC500048471.pdf . Accessed 3 Dec 2016."},{"key":"40_CR31","unstructured":"United States Food and Drug Administration. Velcade: label information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021602s043lbl.pdf . Accessed 03 Oct 2017."},{"key":"40_CR32","unstructured":"European Medicines Agency. Kyprolis: EPAR - product information. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003790\/WC500197692.pdf . Accessed 03 Oct 2017."},{"key":"40_CR33","unstructured":"United States Food and Drug Administration. Kyprolis: label information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202714s016lbl.pdf . Accessed 03 Oct 2017."},{"key":"40_CR34","unstructured":"United States Food and Drug Administration. Ninlaro: label information. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208462s001lbl.pdf . Accessed 03 Oct 2017."},{"key":"40_CR35","unstructured":"European Medicines Agency. Ninlaro: EPAR - product information. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003844\/WC500217620.pdf . Accessed 03 Oct 2017."},{"key":"40_CR36","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195\u2013206.","journal-title":"Lancet Oncol"},{"key":"40_CR37","unstructured":"European Medicines Agency. Farydak: EPAR - product information. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003725\/WC500193298.pdf . Accessed 03 Oct 2017."},{"key":"40_CR38","unstructured":"United States Food and Drug Administration. Farydak: label information. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205353s000lbl.pdf . Accessed 03 Oct 2017."},{"key":"40_CR39","unstructured":"European Medicines Agency. Empliciti: EPAR - product information. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003967\/WC500206673.pdf . Accessed 3 Oct 2017."},{"key":"40_CR40","unstructured":"United States Food and Drug Administration. Empliciti: label information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761035s005lbl.pdf . Accessed 03 Oct 2017."},{"key":"40_CR41","unstructured":"European Medicines Agency. Darzalex: EPAR - product information. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004077\/WC500207296.pdf . Accessed 5 Dec 2016."},{"key":"40_CR42","unstructured":"United States Food and Drug Administration. Darzalex: label information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761036s005lbl.pdf . Accessed 03 Oct 2017."},{"key":"40_CR43","first-page":"1105","volume":"54","author":"NW Donk van de","year":"2016","unstructured":"van de Donk NW, Otten HG, El Haddad O, Axel A, Sasser AK, Croockewit S, et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med. 2016;54:1105\u20139.","journal-title":"Clin Chem Lab Med"},{"key":"40_CR44","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094\u2013103.","journal-title":"Leukemia"},{"key":"40_CR45","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1055\/s-0034-1370793","volume":"40","author":"V Stefano De","year":"2014","unstructured":"De Stefano V, Za T, Rossi E. Venous thromboembolism in multiple myeloma. Semin Thromb Hemost. 2014;40:338\u201347.","journal-title":"Semin Thromb Hemost"},{"key":"40_CR46","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414\u201323.","journal-title":"Leukemia"},{"key":"40_CR47","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1001\/archinte.162.22.2605","volume":"162","author":"J Nagge","year":"2002","unstructured":"Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med. 2002;162:2605\u20139.","journal-title":"Arch Intern Med"},{"key":"40_CR48","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.thromres.2015.07.036","volume":"136","author":"AJ Cate-Hoek ten","year":"2015","unstructured":"ten Cate-Hoek AJ, Weitz JI, Gailani D, Meijer K, Philippou H, Bouman AC, et al. Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thromb Res. 2015;136:S13\u201318.","journal-title":"Thromb Res"},{"key":"40_CR49","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","volume":"11","author":"M Delforge","year":"2010","unstructured":"Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11:1086\u201395.","journal-title":"Lancet Oncol"},{"key":"40_CR50","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817\u201325.","journal-title":"Blood"},{"key":"40_CR51","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","volume":"17","author":"S Arastu-Kapur","year":"2011","unstructured":"Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17:2734\u201343.","journal-title":"Clin Cancer Res"},{"key":"40_CR52","first-page":"133","volume":"1","author":"JJ Kelly","year":"2004","unstructured":"Kelly JJ. The evaluation of peripheral neuropathy. Part I: clinical and laboratory evidence. Rev Neurol Dis. 2004;1:133\u201340.","journal-title":"Rev Neurol Dis"},{"key":"40_CR53","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","volume":"63","author":"SB Park","year":"2013","unstructured":"Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419\u201337.","journal-title":"CA Cancer J Clin"},{"key":"40_CR54","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/leu.2011.346","volume":"26","author":"PG Richardson","year":"2012","unstructured":"Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012;26:595\u2013608.","journal-title":"Leukemia"},{"key":"40_CR55","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431\u201340.","journal-title":"Lancet Oncol"},{"key":"40_CR56","unstructured":"World Health Organization. WHO\u2019s cancer pain ladder for adults. 2016. http:\/\/www.who.int\/cancer\/palliative\/painladder\/en\/ . Accessed 20 Dec 2016."},{"key":"40_CR57","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/01.PHM.0000154905.18445.0F","volume":"84","author":"BR Stacey","year":"2005","unstructured":"Stacey BR. Management of peripheral neuropathic pain. Am J Phys Med Rehabil. 2005;84:S4\u201316.","journal-title":"Am J Phys Med Rehabil"},{"key":"40_CR58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/BF00313638","volume":"230","author":"A Krone","year":"1983","unstructured":"Krone A, Reuther P, Fuhrmeister U. Autonomic dysfunction in polyneuropathies: a report on 106 cases. J Neurol. 1983;230:111\u201321.","journal-title":"J Neurol"},{"key":"40_CR59","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3349\/ymj.2011.52.1.196","volume":"52","author":"WS Lee","year":"2011","unstructured":"Lee WS, Kim DH, Shin SH, Woo SI, Kwan J, Park KS, et al. Complete atrioventricular block secondary to bortezomib use in multiple myeloma. Yonsei Med J. 2011;52:196\u20138.","journal-title":"Yonsei Med J"},{"key":"40_CR60","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3949\/ccjm.77a.09118","volume":"77","author":"JJ Figueroa","year":"2010","unstructured":"Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: as easy as A, B, C. Cleve Clin J Med. 2010;77:298\u2013306.","journal-title":"Cleve Clin J Med"},{"key":"40_CR61","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.4049\/jimmunol.0901596","volume":"183","author":"M Basler","year":"2009","unstructured":"Basler M, Lauer C, Beck U, Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol. 2009;183:6145\u201350.","journal-title":"J Immunol"},{"key":"40_CR62","unstructured":"Advisory Committee for Immunization Practices. Vaccine-specific recommendations. 2016. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/vacc-specific\/ . Accessed 30 Dec 2016."},{"key":"40_CR63","unstructured":"The University of Hong Kong. VZV vaccine for hematopoietic stem cell transplantation (VZIDST). 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02329457 . Accessed 30 Dec 2016."},{"key":"40_CR64","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","volume":"124","author":"EA Stadtmauer","year":"2014","unstructured":"Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, et al. A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921\u20139.","journal-title":"Blood"},{"key":"40_CR65","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa013441","volume":"347","author":"A Hata","year":"2002","unstructured":"Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347:26\u201334.","journal-title":"N Engl J Med"},{"key":"40_CR66","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1086\/514077","volume":"176","author":"RL Redman","year":"1997","unstructured":"Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997;176:578\u201385.","journal-title":"J Infect Dis"},{"key":"40_CR67","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.3324\/haematol.2014.116772","volume":"100","author":"M Hahn","year":"2015","unstructured":"Hahn M, Schnitzler P, Schweiger B, Kunz C, Ho AD, Goldschmidt H, et al. Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica. 2015;100:e285\u2013288.","journal-title":"Haematologica"},{"key":"40_CR68","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1590\/S1807-59322011001200010","volume":"66","author":"CJ Teng","year":"2011","unstructured":"Teng CJ, Liu HT, Liu CY, Hsih CH, Pai JT, Gau JP, et al. Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes. Clinics. 2011;66:2055\u201361.","journal-title":"Clinics"},{"key":"40_CR69","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4065\/84.3.274","volume":"84","author":"P Sampathkumar","year":"2009","unstructured":"Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84:274\u201380.","journal-title":"Mayo Clin Proc"},{"key":"40_CR70","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3122\/15572625-11-3-224","volume":"11","author":"LL MacFarlane","year":"1998","unstructured":"MacFarlane LL, Simmons MM, Hunter MH. The use of corticosteroids in the management of herpes zoster. J Am Board Fam Pract. 1998;11:224\u20138.","journal-title":"J Am Board Fam Pract"},{"key":"40_CR71","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00277-015-2447-3","volume":"94","author":"M Sandherr","year":"2015","unstructured":"Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol. 2015;94:1441\u201350.","journal-title":"Ann Hematol"},{"key":"40_CR72","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107\u201313.","journal-title":"Haematologica"},{"key":"40_CR73","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.13532","volume":"171","author":"BW Teh","year":"2015","unstructured":"Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171:100\u20138.","journal-title":"Br J Haematol"},{"key":"40_CR74","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142\u201352.","journal-title":"N Engl J Med"},{"key":"40_CR75","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","volume":"343","author":"HM Chapel","year":"1994","unstructured":"Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for immunoglobulin replacement therapy in multiple myeloma. Lancet. 1994;343:1059\u201363.","journal-title":"Lancet"},{"key":"40_CR76","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1080\/10428190902856824","volume":"50","author":"P Raanani","year":"2009","unstructured":"Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009;50:764\u201372.","journal-title":"Leuk Lymphoma"},{"key":"40_CR77","first-page":"253","volume":"4","author":"NW Donk van de","year":"2012","unstructured":"van de Donk NW, Gorgun G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012;4:253\u201368.","journal-title":"Cancer Manag Res"},{"key":"40_CR78","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/bjh.12925","volume":"167","author":"MJ Lee","year":"2014","unstructured":"Lee MJ, Wickner P, Fanning L, Schlossman R, Richardson P, Laubach J, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014;167:127\u201331.","journal-title":"Br J Haematol"},{"key":"40_CR79","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11938-007-0054-7","volume":"10","author":"H Westergaard","year":"2007","unstructured":"Westergaard H. Bile Acid malabsorption. Curr Treat Options Gastroenterol. 2007;10:28\u201333.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"40_CR80","doi-asserted-by":"crossref","unstructured":"Andreyev HJ, Davidson SE, Gillespie C, Allum WH, Swarbrick E, British Society of G et al. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut. 2012;61:179\u201392.","DOI":"10.1136\/gutjnl-2011-300563"},{"key":"40_CR81","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","volume":"22","author":"AB Benson 3rd","year":"2004","unstructured":"Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr., et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918\u201326.","journal-title":"J Clin Oncol"},{"key":"40_CR82","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1080\/10428194.2016.1177181","volume":"57","author":"DS Siegel","year":"2016","unstructured":"Siegel DS, Weisel KC, Dimopoulos MA, Baz R, Richardson P, Delforge M, et al. Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leuk Lymphoma. 2016;57:2833\u20138.","journal-title":"Leuk Lymphoma"},{"key":"40_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.112","volume":"6","author":"A Rosenthal","year":"2016","unstructured":"Rosenthal A, Luthi J, Belohlavek M, Kortum KM, Mookadam F, Mayo A, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016;6:e384.","journal-title":"Blood Cancer J"},{"key":"40_CR84","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","volume":"1","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017;1:449\u201354.","journal-title":"Blood Adv"},{"key":"40_CR85","doi-asserted-by":"crossref","unstructured":"Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos MA, Hajek R, et al. Phase 3 study (CLARION) of carfilzomib, melphalan, prednisone (KMP) v bortezomib, melphalan, prednisone (VMP) in newly diagnosed multiple myeloma (NDMM). 16th International Myeloma Workshop: New Delhi; 2017. p. OP-044.","DOI":"10.1016\/j.clml.2017.03.045"},{"key":"40_CR86","doi-asserted-by":"crossref","unstructured":"Russell SD, Lyon A, Lenihan DJ, Moreau P, Joshua D, Chng W-J, et al. Serial echocardiographic assessment of patients (Pts) with relapsed multiple myeloma (RMM) receiving carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd): a Substudy of the phase 3 Endeavor trial (NCT01568866). Blood. 2015;126: abstract 4250.","DOI":"10.1182\/blood.V126.23.4250.4250"},{"key":"40_CR87","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/10245332.2017.1328165","volume":"22","author":"AJ Jakubowiak","year":"2017","unstructured":"Jakubowiak AJ, DeCara JM, Mezzi K. Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Hematology. 2017;22:585\u201391.","journal-title":"Hematology"},{"key":"40_CR88","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.clml.2016.01.008","volume":"16","author":"J Mikhael","year":"2016","unstructured":"Mikhael J. Management of carfilzomib-associated cardiac adverse events. Clin Lymphoma Myeloma Leuk. 2016;16:241\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"40_CR89","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood.V118.21.303.303","volume":"118","author":"S Lonial","year":"2011","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373:621\u201331.","journal-title":"Blood"},{"key":"40_CR90","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.V126.23.1829.1829","volume":"126","author":"PM Voorhees","year":"2015","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551\u201360.","journal-title":"Blood"},{"key":"40_CR91","doi-asserted-by":"crossref","unstructured":"Chari A, Mark TM, Krishnan A, Stockerl-Goldstein K, Usmani SZ, Londhe A, et al. Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States Patients with relapsed or refractory multiple myeloma. ASH: San Diego; 2016. abstract 2142.","DOI":"10.1182\/blood.V128.22.2142.2142"},{"key":"40_CR92","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Nahi H, Mateos M-V, Lokhorst HM, Chari A, Kaufman JL, et al. Open-label, multicenter, dose escalation phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (PAVO). ASH: San Diego, CA; 2016. abstract 1149.","DOI":"10.1182\/blood.V128.22.1149.1149"},{"key":"40_CR93","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143\u2013238.","journal-title":"Biol Blood Marrow Transplant"},{"key":"40_CR94","doi-asserted-by":"crossref","unstructured":"Cheuk DK, Chiang AK, Lee TL, Chan GC, Ha SY. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev. 2011; CD006505.","DOI":"10.1002\/14651858.CD006505.pub2"},{"key":"40_CR95","first-page":"1167","volume":"24","author":"LM Boehmer","year":"2010","unstructured":"Boehmer LM, Waqar SN, Govindan R. Influenza vaccination in patients with cancer: an overview. Oncology. 2010;24:1167\u201370.","journal-title":"Oncology"},{"key":"40_CR96","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/infdis\/jit365","volume":"208","author":"R Chlibek","year":"2013","unstructured":"Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults>=50 years of age. J Infect Dis. 2013;208:1953\u201361.","journal-title":"J Infect Dis"},{"key":"40_CR97","doi-asserted-by":"crossref","unstructured":"Mallet V, van Bommel F, Doerig C, Pischke S, Hermine O, Locasciulli A, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16: 606\u201317.","DOI":"10.1016\/S1473-3099(16)00118-3"},{"key":"40_CR98","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2215\/CJN.06100616","volume":"12","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Abudayyeh A, Doshi M, Edeani A, Glezerman IG, Monga D, et al. Renal toxicities of novel agents used for treatment of multiple myeloma. Clin J Am Soc Nephrol. 2017;12:176\u201389.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0040-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0040-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0040-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:33:10Z","timestamp":1684618390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0040-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":98,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["40"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0040-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"10 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HL has received speakers\u2019 honoraria from Celgene, Amgen, Takeda, Janssen, and Bristol-Myers Squibb, and research funding from Takeda and Amgen, as well as consultancy fees from Amgen, Takeda, and Janssen. MD has received speakers\u2019 honoraria and consultancy fees from Amgen, Takeda, Janssen, Celgene, and Bristol-Myers Squibb, as well as research support from Celgene and Janssen. TF has received speakers\u2019 honoraria and honoraria for participation in advisory boards from Celgene, Janssen, Takeda, Amgen, and PharmaMar. HE has received speakers\u2019 honoraria and honoraria for participation in advisory boards for Celgene, Janssen, Amgen, Bristol-Myers Squibb, and Novartis, and consultancy fees or honoraria from Celgene, Janssen, Bristol-Myers Squibb, and Amgen. FG has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, and Takeda, and honoraria for participation in advisory boards from Janssen, Amgen, Celgene, Roche, and Takeda. PM has received honoraria from Novartis, Janssen, Celgene, Millennium, Onyx, and Bristol-Myers Squibb, and consultancy fees from Novartis, Janssen, Celgene, Millennium, and Onyx. HA-L has received honoraria for participation in advisory boards from Celgene, Janssen, Amgen, and Sanofi, and research funding from Celgene and Sanofi. RH has received consultancy fees, research funding, and honoraria for participation in advisory boards from Amgen, Takeda, Bristol-Myers Squibb, Celgene, Novartis, and Janssen. MM has received honoraria and research funding from Janssen, Celgene, Amgen, Takeda, Novartis, and Bristol-Myers Squibb. MC has received consultancy fees from Janssen, Celgene, Amgen, and Bristol-Myers Squibb, speakers\u2019 honoraria from Janssen, Celgene, Amgen, and Takeda, honoraria for participation in advisory boards from Janssen, Celgene, Takeda, Amgen, and Bristol-Myers Squibb, as well as honoraria from Janssen, Celgene, Bristol-Myers Squibb, Amgen, Novartis, and Takeda. MAD has received consultancy fees and honoraria from Celgene, Onyx, Janssen, Novartis, and Amgen, and honoraria for participation in advisory boards from Amgen, Takeda, Celgene, and Janssen. JS-M has received speaker\u2019s honoraria and consultancy fees from Takeda, Celgene, Novartis, Amgen, Janssen, Bristol-Myers Squibb, Sanofi, and MSD. ET has received honoraria from Janssen, Amgen, Takeda, Abbvie, Bristol-Myers Squibb, PharmaMar, and Celgene, research funding from Amgen, Genesis, Janssen, Novartis, and Takeda, honoraria for participation in advisory boards from Takeda, as well as honoraria for participation in the data monitoring committee from Celgene. SZ has received honoraria for participating in advisory boards and research funding from Janssen, Celgene, Novartis, and Takeda. M-VM has has received personal fees from Janssen, Celgene, BMS, Amgen, and Takeda. GC has received consultancy fees and research funding from Janssen, Celgene, Takeda, Sanofi, Amgen, and Bristol-Myers Squibb. XL has received honoraria for participating in advisory boards and honoraria from Celgene, Janssen, Takeda, Amgen, Novartis, Sanofi, BMS, Merck, Pierre Fabre, and Gilead. HG has received research funding and honoraria from Celgene, Chugai, Novartis, Janssen, and Bristol-Myers Squibb, and honoraria for participating in advisory boards from Janssen, Celgene, Novartis, Amgen, Takeda, and Bristol-Myers Squibb. GJ has received speakers\u2019 honoraria and honoraria for participating in advisory boards from Takeda, Celgene, Janssen, Amgen, and Roche, and research funding from Onyx, Celgene, and CRUK. MK received research funding from Celgene, and honoraria for participating in advisory boards from Takeda, Celgene, Amgen, Janssen, and Bristol-Myers Squibb. KW has received honoraria from Novartis, Janssen, Celgene, Amgen, Onyx, Takeda, and Bristol-Myers Squibb, and consultancy fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Takeda, and Onyx. NvdD has received research funding and honoraria for participating in advisory boards from Janssen, Celgene, Bristol-Myers Squibb, and Amgen. AW has received research support from Amgen and Celgene, and honoraria for participation in advisory boards from Amgen, Celgene, and Takeda. MB has received honoraria for participating in advisory boards from Novartis, Amgen, Celgene, and Janssen, and speakers\u2019 honoraria from Amgen, Celgene, and Janssen. U-HM has received honoraria for participating in advisory boards from Amgen and Takeda, and honoraria from Amgen, Celgene, Takeda, Mundipharma, Janssen, and Novartis. PS has received honoraria for participating in advisory boards and honoraria from Celgene, Janssen, Amgen, Karyopharm, and Takeda. MB, JC, CD, ME, and LG declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}